Department of Synthetic Natural Products Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
Department of Microbial Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
ChemMedChem. 2018 Mar 6;13(5):411-421. doi: 10.1002/cmdc.201700645. Epub 2018 Jan 30.
Currently, pyripyropene A, which is isolated from the culture broth of Aspergillus fumigatus FO-1289, is the only compound known to strongly and selectively inhibit the isozyme sterol O-acyltransferase 2 (SOAT2). To aid in the development of new cholesterol-lowering or anti-atherosclerotic agents, new A-ring simplified pyripyropene A analogues have been designed and synthesized based on total synthesis, and the results of structure-activity relationship studies of pyripyropene A. Among the analogues, two A-ring simplified pyripyropene A analogues exhibited equally efficient SOAT2 inhibitory activity to that of natural pyripyropene A. These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
目前,从烟曲霉 FO-1289 的发酵液中分离得到的吡嗪并吡喃酮 A 是唯一一种已知能强烈且选择性地抑制同工酶甾醇 O-酰基转移酶 2(SOAT2)的化合物。为了开发新的降胆固醇或抗动脉粥样硬化药物,根据全合成以及吡嗪并吡喃酮 A 的结构-活性关系研究结果,设计并合成了新的 A 环简化吡嗪并吡喃酮 A 类似物。在这些类似物中,两个 A 环简化吡嗪并吡喃酮 A 类似物对 SOAT2 的抑制活性与天然吡嗪并吡喃酮 A 相当。这些新的类似物是最有效和选择性的 SOAT2 抑制剂,可作为合成化合物使用,并为开发用于治疗血脂异常的药物,包括动脉粥样硬化疾病和脂肪变性,提供有吸引力的起始化合物。